株式会社Veritas In Silico Logo

株式会社Veritas In Silico

An in silico drug discovery platform creating mRNA-targeting medicines with pharma partners.

130A | T

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
Japan
Address:
品川区西五反田一丁目11番1号
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

Veritas In Silico Inc. is a drug discovery platform company specializing in the creation of small molecule and nucleic acid medicines that target messenger RNA (mRNA). The company utilizes its proprietary *in silico* (computational simulation) technologies, combining quantum chemistry calculations with robust high-throughput screening, to design novel therapeutics for previously undruggable targets. Its core business involves establishing joint research and development partnerships with major pharmaceutical companies, earning revenue through milestone payments and future royalties. Veritas In Silico has secured numerous collaborations with leading firms such as Takeda, Shionogi, and Mitsubishi Gas Chemical. The company was listed on the Tokyo Stock Exchange Growth Market in February 2024.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-14 08:00
Interim Report
半期報告書-第10期(2025/01/01-2025/12/31)
Japanese 177.7 KB
2025-08-14 08:00
Interim Report
確認書
Japanese 8.8 KB
2025-03-28 05:18
Post-Annual General Meeting Information
臨時報告書
Japanese 27.1 KB
2025-03-28 02:47
Regulatory News Service
内部統制報告書-第9期(2024/01/01-2024/12/31)
Japanese 22.5 KB
2025-03-28 02:47
Regulatory News Service
確認書
Japanese 8.8 KB
2025-03-28 02:46
Annual Report
有価証券報告書-第9期(2024/01/01-2024/12/31)
Japanese 3.1 MB
2024-08-14 08:00
Interim Report
確認書
Japanese 8.7 KB
2024-08-14 08:00
Interim Report
半期報告書-第9期(2024/01/01-2024/12/31)
Japanese 171.1 KB
2024-05-15 09:55
Report Publication Announcement
確認書
Japanese 8.7 KB
2024-05-15 08:00
Quarterly Report
四半期報告書-第9期第1四半期(2024/01/01-2024/03/31)
Japanese 146.8 KB
2024-03-15 07:01
Post-Annual General Meeting Information
臨時報告書
Japanese 23.2 KB
2024-03-15 07:00
Annual Report
有価証券報告書-第8期(2023/01/01-2023/12/31)
Japanese 3.1 MB
2024-02-08 01:05
Regulatory News Service
臨時報告書
Japanese 21.1 KB
2024-01-31 07:00
Registration Form
訂正有価証券届出書(新規公開時)
Japanese 2.4 MB
2024-01-23 07:00
Registration Form
訂正有価証券届出書(新規公開時)
Japanese 2.4 MB

Automate Your Workflow. Get a real-time feed of all 株式会社Veritas In Silico filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for 株式会社Veritas In Silico via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Biotech R&D using a miniature pig model, offering CRO services and biomaterials to pharma.
South Korea 149300
Arterra Bioscience Logo
Develops natural active ingredients via biotechnology for cosmetic, pharma, and food sectors.
Italy ABS
ASUA Inc. Logo
Consulting and solutions provider enhancing logistics safety and efficiency with IoT and telecom.
Japan 246A
Licenses patented material IP (MST®) to create higher-performance, lower-power semiconductors.
United States of America ATOM
Atrae, Inc. Logo
Develops People Tech solutions for HR, including big data job sites and organizational analytics.
Japan 6194
Developing uranium and battery minerals for the nuclear energy and energy storage markets.
Australia N/A
BayCurrent, Inc. Logo
Comprehensive consulting on strategy, AI, and digital transformation for corporations and government.
Japan 6532
BenevolentAI Logo
An AI-powered drug discovery platform accelerating R&D for scientists and pharmaceutical partners.
United Kingdom BAI
BerGenBio Logo
Develops first-in-class AXL kinase inhibitors for cancer and severe respiratory infections.
Norway BGBIO
Bergman & Beving Logo
Acquires and develops niche companies with solutions for the industrial and construction sectors.
Sweden BERG

Talk to a Data Expert

Have a question? We'll get back to you promptly.